£2.9M
Parkwalk led the round to help the University of Cambridge spinout expand its manufacturing and commercial reach.
CC
Cambridge Capital Group
AngelPortfolio
6
companies
Investment by month
By category
- Semiconductor£6.8M
- BioTech£4.4M
- AI/ML£3.7M
- MedTech£1.0M
By location
- Cambridge£15.2M
- Norwich£650K
Portfolio companies
CG
Cambridge GaN Devices
Developer of power semiconductor devices using Gallium-Nitride on Silicon technology.
D
DefiniGEN
DefiniGEN creates human cell models to support drug discovery and preclinical research.
P
PneumaCare
PneumaCare develops non-invasive respiratory diagnostic and monitoring equipment.
Rainbird
Cloud based artificial intelligence platform for enterprise applications.
S
Semarion
Semarion develops microcarrier technology that turns adherent cells into assay-ready reagents.
Spotta
Spotta creates connected monitoring devices for insect pest management across various industries.
Recent investments
£3.0M
The funding round was led by The Yield Lab, STIHL Ventures, and ACF Investors to drive global product growth.
"The Spotta platform built by Robert, Neil and the team delivers a real solution which can completely turn the insect pest control industry on its head. With their smart 24/7 monitoring enabling customers to precision target treatment for the first time. It’s a solution that protects people and crops but also hugely reduces the cost and environmental impact of treatment."
The Yield Lab + 8 others
$9.5M
The financing round was co-led by IQ Capital, Parkwalk Advisors and BGF to scale the company's product range and double headcount.
"This latest round of investment is a great recognition of our success to date, with new and existing investors confirming the strength of our technology. Since 2016, CGD has grown significantly and we are thrilled to be in a position to deliver several products to market, following decades of industry-leading research in reliability of power devices. This investment will allow us to supplement our experienced team with additional experts and expand our markets globally, creating more sustainable electronics worldwide."
The funding supports the development of power semiconductor devices based on Gallium-Nitride technology.
£1.5M
The follow-on investment will fund the commercial launch of new pancreatic and lung stem cell products.
"In a short space of time, DefiniGEN has undergone rapid development, securing growing sales with global pharma companies. We are delighted to have raised the funds that will allow us to deliver new market-leading products to our customers and assist them in developing therapies for the global healthcare challenges we face today such as diabetes and liver disease."
